Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Giles

Showing results (461-470 of 610) with videos related to

Pageof 61
Sort By:
Leukemia Research|May 4, 2004
Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphomaFrancis J Giles, Julie M Vose, Kim-Anh Do, et al.
Neuro-Oncology Advances|April 11, 2022
Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignanciesYazmin Odia, Ludimila Cavalcante, Howard Safran, et al.
Cancer|August 27, 2004
Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodiesMaher Albitar, Kim-Anh Do, Marcella M Johnson, et al.
Leukemia Research|December 17, 2013
Nilotinib 300 mg BID as frontline treatment of CML: prospective analysis of the Xpert BCR-ABL monitor system and significance of 3-month molecular responseMichael E O'Dwyer, Ronan Swords, Arnon Nagler, et al.
British Journal of Haematology|October 3, 2002
Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survivalFrancis J Giles, Hagop M Kantarjian, B Nebiyou Bekele, et al.
Blood|August 1, 2002
The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemiaAlessandra Ferrajoli, Michael J Keating, Taghi Manshouri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myelomaMaurizio Zangari, Elias Anaissie, Alison Stopeck, et al.
Hematology (Amsterdam, Netherlands)|July 14, 2016
Skin Necrosis Associated With Heparin-Induced Thrombocytopenia and ThrombosisF J Giles, T J Kanemaki, J T Otsuki, et al.
Leukemia|April 18, 2006
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndromeG J Roboz, F J Giles, A F List, et al.
Cancer|December 12, 2003
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic dataHagop M Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Pageof 61

Showing results (461-470 of 610) with videos related to

Sort By:
Pageof 61
Leukemia Research|May 4, 2004
Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphomaFrancis J Giles, Julie M Vose, Kim-Anh Do, et al.
Neuro-Oncology Advances|April 11, 2022
Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignanciesYazmin Odia, Ludimila Cavalcante, Howard Safran, et al.
Cancer|August 27, 2004
Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodiesMaher Albitar, Kim-Anh Do, Marcella M Johnson, et al.
Leukemia Research|December 17, 2013
Nilotinib 300 mg BID as frontline treatment of CML: prospective analysis of the Xpert BCR-ABL monitor system and significance of 3-month molecular responseMichael E O'Dwyer, Ronan Swords, Arnon Nagler, et al.
British Journal of Haematology|October 3, 2002
Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survivalFrancis J Giles, Hagop M Kantarjian, B Nebiyou Bekele, et al.
Blood|August 1, 2002
The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemiaAlessandra Ferrajoli, Michael J Keating, Taghi Manshouri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myelomaMaurizio Zangari, Elias Anaissie, Alison Stopeck, et al.
Hematology (Amsterdam, Netherlands)|July 14, 2016
Skin Necrosis Associated With Heparin-Induced Thrombocytopenia and ThrombosisF J Giles, T J Kanemaki, J T Otsuki, et al.
Leukemia|April 18, 2006
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndromeG J Roboz, F J Giles, A F List, et al.
Cancer|December 12, 2003
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic dataHagop M Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Pageof 61